APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, and recommended dose
schedule of APL-501 in individuals with advanced or relapsed or recurrent solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Apollomics (Australia) Pty. Ltd. CBT Pharmaceuticals, Inc.
Collaborators:
Apollomics Inc. (formerly CBT Pharmaceuticals, Inc.) Novotech (Australia) Pty Limited